Navigation Links
Arpida Announces Conference Call on 17 April
Date:4/15/2008

REINACH, Switzerland, April 15 /PRNewswire-FirstCall/ -- Arpida Ltd. (SWX: ARPN) today announced that it will host a conference call on Thursday 17 April 2008 at 8.30am CET. In this conference call, a leading expert will discuss the medical need and developments in the area of anti-infective drugs as well as the outcome of a recent meeting of the Anti-Infective Drugs Advisory Committee. During that meeting, the committee discussed product development and clinical trial design for both mild/moderate and moderate/severe community acquired pneumonia (CAP). A primary objective for the committee deliberations was to discuss issues relating to clinical trial design.

During the conference call, Arpida will also discuss the clinical data from the ASSIST-1 and ASSIST-2 trials with intravenous iclaprim in complicated Skin and Skin Structure Infections (cSSSI). In addition, the pooled analysis of the clinical data from these two pivotal Phase III trials will be discussed. Part of the data has already been published in earlier press releases, some additional statistical data, not previously published, will also be discussed. All data, as well as the dial-in details, will be made available via a press release on 17 April, prior to the conference call.

About Arpida Ltd.

Arpida (SWX: ARPN) is a biopharmaceutical company with research facilities in Reinach, Switzerland and in the USA. It focuses on the discovery and development of novel drugs that seek to overcome the growing problem of microbial resistance. The most advanced compounds include an antibacterial under regulatory review and an antifungal in Phase III.

Arpida's leading product candidate is intravenous iclaprim, a potent antibacterial that targets severe infections requiring hospital treatment, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). The clinical programme for the first indication, complicated skin and skin structure infections (cSSSI), has been co
'/>"/>

SOURCE Arpida Ltd.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Arpida Interim Results for six Months to 30 June 2007
2. Arpida Invited to Present Preclinical Data on Novel Topical Antibiotic AR-2474 at ICAAC
3. Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC
4. Arpida Presents Preclinical Data on AR-2474 at ICAAC
5. Arpida Presents Data on Iclaprim at Scientific Congress in Germany
6. Arpida-Supported CME Symposium Available Online
7. Arpida Receives Green Light From US FDA for Phase II Efficacy Trial With Oral Iclaprim
8. Arpida Reports Progress in Pivotal Phase III Trial With TLT Treatment in Onychomycosis
9. Arpida Provides Update on Progress of New Drug Application for Intravenous Iclaprim
10. Arpida Announces Full Year 2007 Financial Results
11. Arpida Submits New Drug Application for Intravenous Iclaprim for Treatment of Skin Infections
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... leading provider of strategic communications services to corporations and organizations preparing ... the United States and Europe , ... returning to the firm,s Washington, D.C. office. ... two years of service as Associate Commissioner for the Office of ...
(Date:1/14/2014)... 14, 2014 EquitiesIQ, a leading informational ... ALQA). Alliqua is an emerging biomedical company acquiring, developing, ... care market. , Free report download: http://equitiesiq.com/reports/alliqua/ ... seasoned management team and Board, which launched the company’s ...
(Date:1/14/2014)... BETHESDA, Md. , Jan. 14, 2014  Organovo ... institutes from the National Institutes of Health (NIH) to ... more effective treatments to patients on a faster timeline. ... Translational Sciences (NCATS) and the National Eye Institute (NEI) ...
(Date:1/14/2014)... January 14, 2014 In recent years, ... and methods in product development and promotion has led ... This mistrust, fueled by concerns about the insidious impact ... reports of spectacular fines to the world’s biggest pharmas ...
Breaking Biology Technology:Former FDA Associate Commissioner Returns To 3D Communications 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 2EquitiesIQ Initiates Coverage of Alliqua, Inc. 3Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3
... layer of carbon atoms, may be the most amazing ... yet lightweight and flexible, graphene enables electrons to flow ... conductor, combining electrical and optical functionalities in an exceptional ... sustainable carbon revolution, with profound impact in information and ...
... GeoVax Labs, Inc. (OTCBB: GOVX), a biotechnology company ... today released its 2010 Annual Report and President,s ... (10-K) provides information on the state of the ... his Letter, GeoVax,s President Robert T. McNally, Ph.D., ...
... 2011 Bacterin International Holdings, Inc. ("Bacterin") (NYSE Amex: ... today announced that its chairman and CEO, Guy Cook, will ... Conference at the Hard Rock Hotel in Hollywood, Florida, on ... At the time of the presentation, a live audio and ...
Cached Biology Technology:GRAPHENE-CA appointed an EU Future Emerging Technology flagship pilot 2GeoVax Labs Announces Availability of 2010 Annual Report and President's Letter to Stockholders 2Bacterin International to Present at Noble Financial Capital Markets' Seventh Annual Equity Conference on May 16, 2011 2
(Date:4/24/2014)... that the world,s oceans play a crucial role ... between Earth,s ecosystems and atmosphere. Now scientists at ... have taken a leap forward in understanding the ... use carbon dioxide to make new cells, a ... into the sea as a buffet of edible ...
(Date:4/24/2014)... NY, April 24, 2014GEN Publishing recently introduced ... publication focusing on the application of OMICs technologies ... next-gen sequencing, are beginning to transform medical care ... over the past decade-and-a-half. , "GEN,s editors and ... pharmacogenomics, genomics, metabolomics, transcriptomics, etc. etc. for years," ...
(Date:4/24/2014)... Scientific Reports journal. , CSIC researcher Carles Lalueza-Fox, ... CSIC and Pompeu Fabra University-UPF), explains: "When the Y chromosome ... it did not match with the DNA recovered from the ... and to make a functional interpretation in order to see ... , The functional genome analysis was based on two main ...
Breaking Biology News(10 mins):Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 2Microscopic organism plays a big role in ocean carbon cycling, Scripps scientists discover 3The blood preserved in the pumpkin did not belong to Louis XVI 2
... compared to last year,s record size. According to measurements made by ... tonnes, compared to the 2006 record ozone loss of 40 million ... the depth of the ozone hole. The area of this years ... Units is 24.7 million sq km, roughly the size of ...
... A team of UAB geneticists, doctors and biostatisticians has ... to study and test new treatments for neurofibromatosis, or ... a nine-institution group called the NF Consortium. The coalition ... manage multiple clinical trials held across the nation looking ...
... Keck School of Medicine of the University of Southern California ... T. & Eileen L. Norris Foundation that will be critical ... to the study of epigenetics. The grant will solidify ... holds great promise in the treatment and prevention of cancer, ...
Cached Biology News:2007 ozone hole 'smaller than usual' 22007 ozone hole 'smaller than usual' 3UAB wins $5.7M neurofibromatosis grant 2UAB wins $5.7M neurofibromatosis grant 3$10 million gift to support cutting-edge epigenome center at USC 2$10 million gift to support cutting-edge epigenome center at USC 3
... IVF are designed for human in vitro ... setup and operation, and convenience. Chamber, ... displayed on the control panel. Our signature ... by way of the thermal printer inside ...
Anti-VDAC (Voltage-Dependent Anion Channel) AVOID FREEZE/THAW CYCLES. Recognizes the porin 31HL protein. Corresponds to mAb 1 in the literature....
... Crotalus adamanteus venom Description: Phosphodiesterase ... used in studying nucleic acid ... It hydrolyzes 5'-mononucleotides from 3'-hydroxy-terminated ... Phosphodiesterase I cleaves ADP-ribosylated proteins ...
A powerful, easy-to-use solution, the SORVALL RC12BP Blood Processing System allows you to manufacture blood components quickly and cost-effectively while ensuring product quality, safety, and GMP co...
Biology Products: